Eldecalcitol
Based on 5 publication(s) in Google Scholar
Eldecalcitol (ED-71) is an orally active vitamin D3 analogue, inhibits bone resorption and increases bone mineral density. Eldecalcitol (ED-71) displays anti-tumor effect and inhibits cell proliferation, migration and induces apoptosis by suppressing GPx-1.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.91%
- CAS No.: 104121-92-8
- Formule: C30H50O5
- Masse moléculaire:490.72
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Eldecalcitol
More
Activité biologique
Description
In Vitro
Eldecalcitol (0-50 nM; 24 h) displays no cytotoxicity, and (0.5-50 nM; 24 h) reduces cell death induced by LPS (5 μg/mL)[2].
Eldecalcitol (5 nM; 24 h) inhibits the LPS-induced pyroptosis by activating Nrf2 and its effector molecule HO-1[2].
Eldecalcitol (0.5-50 nM; 24 h) exhibits anti-pyroptotic ability, and decreases NLRP3, caspase-1, and IL-1β expression dose-dependently[3].
Eldecalcitol (0.04-40 nM; 0-48 h) inhibits the proliferation and migration of SCC-15 and CAL-27 cells[3].
Eldecalcitol (0.4 nM; 48 h) arrests cell cycle at G0/G1 phase and induces apoptosis by suppressing the expression of GPx-1 (glutathione peroxidase) in OSCC cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human gingival fibroblasts (HGFs)
-
Concentration:0, 0.5, 5, and 50 nM
-
Incubation Time:24 hours
-
Result:Decreased TLR4, NLRP3, caspase-1 p20, ASC, and GSDMD-N level in a dose-dependent manner compared with the group treated with LPS.
Reduced the release of IL-1β and IL-18 induced by LPS to normal levels.
-
Cell Line:SCC-15 and CAL-27 cells
-
Concentration:0, 0.04, 0.4, 4, and 40 nM
-
Incubation Time:6, 8, 12, 24, 48 hours
-
Result:Inhibited the cell viability of the OSCC cells to reach 50% at 24 h with 0.4 nM.
-
Cell Line:OSCC cells
-
Concentration:0.4 nM
-
Incubation Time:48 hours
-
Result:Increased the proportion of cells at the late phases of apoptosis from 7.1% to 16.1%.
Upregulated Bax and caspase-3, downregulated Bcl-2.
Significantly triggered apoptosis in SCC- 15 and CAL- 27 cells.
In Vivo
Eldecalcitol (10, 30, or 90 ng/kg; p.o.; 5-times per week for 12 weeks), as a more potent vitamin D3 analog, stimulates focal bone formation (minimodeling) and suppresses bone resorption more strongly than does calcitriol[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Xenograft tumor model in mice (male athymic nude BALB/c mice)[3]
-
Dosage:0.5 μg/kg
-
Administration:Oral gavage; twice a week for 4 weeks
-
Result:Reduced the growth rate of tumors, and downregulated the expression levels of PCNA and MMP- 2 and upregulated the expression of Bax in the tumors.
Resulted in decrease of proliferation, the inhibition of migration, and the promotion of apoptosis.
-
Animal Model:Ovariectomized (OVX) rat model[4]
-
Dosage:10, 30, or 90 ng/kg
-
Administration:Oral gavage; 5-times per week for 12 weeks
-
Result:Increased the lumbar and femoral BMD in a dose dependent manner. Stimulated focal bone formation that started without prior bone resorption, a process known as bone minimodeling.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 104121-92-8
-
Appearance Solid
-
Masse moléculaire 490.72
-
Formule C30H50O5
-
Color White to off-white
-
SMILES
O[C@H]1[C@@H](OCCCO)[C@H](O)C(/C(C1)=C\C=C2[C@]3([H])CC[C@H]([C@H](C)CCCC(C)(O)C)[C@@]3(C)CCC\2)=C
-
Synonyms
ED-71; 2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin D3
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Cell Prolif
Glutaminase-1 Mediated Glutaminolysis to Glutathione Synthesis Maintains Redox Homeostasis and Modulates Ferroptosis Sensitivity in Cancer Cells. [Abstract]2025 Nov;58(11):e70036. PMID: 40259435 -
Eur J Pharmacol
ED-71 ameliorates bone regeneration in type 2 diabetes by reducing ferroptosis in osteoblasts via the HIF1α pathway. [Abstract]2024 Apr 15:969:176303. PMID: 38211715 -
Virol Sin
Antiviral activity of vitamin D derivatives against severe fever with thrombocytopenia syndrome virus in vitro and in vivo. [Abstract]2024 Oct;39(5):802-811. PMID: 39168248 -
Bone
Sympathetic overactivity-induced type H endothelial cell senescence contributes to the impairment of vascularized osteogenesis by PKM2-mediated glycolysis in preclinical stages of Alzheimer's mice. [Abstract]2026 Jun:207:117859. PMID: 41833832 -
Tissue Cell
Eldecalcitol enhances osteo/odontogenic differentiation and mineralized matrix formation via redox modulation in human dental pulp stem cells. [Abstract]2026 May 2:102:103565. PMID: 42096965
Solvant et solubilité
In Vitro:
DMSO : 3.33 mg/mL (6.79 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (280 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Matsumoto T.Osteoporosis Treatment by a New Active Vitamin D3 Compound, Eldecalcitol, in Japan.Curr Osteoporos Rep. 2012 Aug 24. [Content Brief]
[2]. Huang C, et al. Eldecalcitol Inhibits LPS-Induced NLRP3 Inflammasome-Dependent Pyroptosis in Human Gingival Fibroblasts by Activating the Nrf2/HO-1 Signaling Pathway. Drug Des Devel Ther. 2020 Nov 13;14:4901-4913. [Content Brief]
[3]. Lu Y, et al. Eldecalcitol inhibits the progression of oral cancer by suppressing the expression of GPx-1. Oral Dis. 2021 Aug 24. [Content Brief]
[4]. Saito H, et al. Eldecalcitol and calcitriol stimulates 'bone minimodeling,' focal bone formation without prior bone resorption, in rat trabecular bone. J Steroid Biochem Mol Biol. 2013 Jul;136:178-82. [Content Brief]
Complete Stock Solution Preparation Table
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0378 mL | 10.1891 mL | 20.3782 mL | 50.9455 mL |
| 5 mM | 0.4076 mL | 2.0378 mL | 4.0756 mL | 10.1891 mL |
Eldecalcitol Related Classifications
HY-A0020 Related Classifications
Powered by Bioz
Keywords
- Eldecalcitol
- 104121-92-8
- ED-71
- 2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin D3
- ED71
- ED 71
- VD/VDR
- Apoptosis
- bone
- resorption
- mineral
- density
- periodontitis
- NLRP3 inflammasome
- human gingival fibroblasts
- HGFs
- LPS-induced
- pyroptosis
- Nrf2/HO-1
- osteoporosis
- anti-tumor
- proliferation
- migration
- GPx-1
- arrest cell cycle
- Inhibitor
- inhibitor
- inhibit